美國科學家兩項不同研究顯示，血液中總膽固醇水平低可能有助降低男性罹患前列腺癌的幾率，而血液中“好”膽固醇水平高則可能有助預防癌癥,。
或有助防癌
美國國家癌癥研究所高級研究員迪米特里厄斯·奧爾本斯在《癌癥流行病學、生物標記與預防》11月這一期上發(fā)表論文說,，經過對2．9萬名芬蘭人18年跟蹤調查后發(fā)現(xiàn),，總膽固醇水平低或有助防癌。
成年人每分升血液中總膽固醇量低于200毫克屬于膽固醇水平低,。一些醫(yī)學界人士先前認為,，膽固醇水平低可能會引發(fā)癌癥。
奧爾本斯研究發(fā)現(xiàn),，膽固醇水平低的調查對象患癌幾率高18％,，而這些病患都在研究早期被確認罹患癌癥。他在論文編者按中寫道,，這些結果表明,，膽固醇水平低不是癌癥的前因，而是后果,。
研究還發(fā)現(xiàn),，“好”膽固醇即高密度脂蛋白水平高的調查對象比“好”膽固醇低的調查對象罹患各種癌癥幾率低14％。
降患癌幾率
同期《癌癥流行病學,、生物標記與預防》上另一篇論文指出,，血液中膽固醇水平低于每分升200毫克的男性，罹患高格利森分數(shù)前列腺癌的幾率低59％,。格利森分數(shù)表明癌癥的惡化程度,，分數(shù)越高越難治療。
領導這項研究的是約翰斯·霍普金斯大學金梅爾癌癥研究中心負責人之一伊麗莎白·普拉茨,。普拉茨帶領研究人員分析了5586名55歲以上男性的健康數(shù)據(jù),，發(fā)現(xiàn)膽固醇水平并非與所有程度的前列腺癌有顯著關聯(lián)，只與格利森分數(shù)高的前列腺癌有關,。
研究人員綜合考慮了受調查者吸煙歷史,、體重、前列腺癌家族史和膳食膽固醇這些因素得出上述結論,，其他因素也可能影響研究結果,。
待深入研究
主持兩項研究的科學家均表示，膽固醇水平與癌癥關系有待進一步研究,。
奧爾本斯說,，“好”膽固醇水平高可能有助防癌是一項新發(fā)現(xiàn),，還有待在其他研究中，譬如女性身上進一步證明,。
他說：“對于降低膽固醇水平的作用,，我們并未收集到具體數(shù)據(jù)。根據(jù)我們的研究得出低膽固醇水平有助抗癌的結論也許為時尚早,。”
普拉茨則表示,，需要進一步研究降膽固醇抑制素藥物是否有助男性預防前列腺癌。
她說：“不斷有證據(jù)表明,，降膽固醇抑制素藥物與罹患前列腺癌的幾率有關,。”（生物谷Bioon.com）
生物谷推薦原始出處：
Cancer Epidemiology, Biomarkers & Prevention October 1, 2009 18, 2643
Serum Creatinine and Prostate Cancer Risk in a Prospective Study
Stephanie J. Weinstein1, Katrina Mackrain1, Rachael Z. Stolzenberg-Solomon1, Jacob Selhub2, Jarmo Virtamo3 and Demetrius Albanes1
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland; 2Jean Mayer U.S. Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts; and 3Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
Background: Several studies have examined serum creatinine as a marker for prostate cancer stage, recurrence, and prognosis. We evaluated whether serum creatinine concentration was associated with risk of developing prostate cancer in a prospective cohort of male smokers.
Methods: A nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study of 50- to 69-year-old Finnish men was conducted. Two controls (n = 464) were matched to each case (n = 232) on study center, intervention group, date of baseline blood draw (±45 days), and age (±5 years). Conditional logistic regression was used to calculate odds ratios and 95% confidence intervals. All P values were two-sided.
Results: Cases had significantly higher prediagnostic serum creatinine concentrations compared with controls (medians of 1.13 versus 1.10 mg/dL, respectively; P = 0.004). Serum creatinine was associated with a significantly greater risk of prostate cancer (multivariate odds ratio, 2.23; 95% confidence interval, 1.33-3.75 for highest versus lowest quartile), with a significant trend (P trend = 0.0008). Exclusion of subjects with a reported history of diabetes, benign prostatic hyperplasia, or hypertension, or whose cancer was diagnosed within the first 5 years of follow-up, did not alter the association. Risk did not differ by disease stage or time from blood draw to diagnosis.
Conclusion: Prospectively measured serum creatinine, within normal ranges, is positively related to prostate cancer risk. Future research should reexamine the association in other populations, including any interrelationship with serum prostate-specific antigen.
